Paragonix Launches PancreasPak™: The First FDA-Cleared Device for Preserving Donor Pancreases in Transplantation

Friday, June 28, 2024

Paragonix Technologies has unveiled the PancreasPak™ Organ Preservation System, the first FDA-cleared device designed to protect and monitor donor pancreases during transportation.

Pre-orders for this innovative technology begin on June 27, 2024, with full availability set for September 1, 2024.

The PancreasPak™ System is poised to transform pancreatic transplantation by leveraging Paragonix’s SherpaPak® Cardiac Transport System principles, widely adopted in a significant number of US cases.

It promises unprecedented monitoring and control, maintaining the pancreas at an optimal thermal range of 4-8°C for up to 21 hours. This advanced approach aims to minimize ischemic times, improve post-transplant outcomes, and enhance 2-year patient survival rates.

Department of Surgery at the Medical University of South Carolina, highlighted the significance of this innovation: "An advanced preservation device tailored to our needs promises to substantially enhance organ viability and patient outcomes."

The company's commitment to advancing transplant medicine: "Introducing this technology to the pancreatic transplant community reflects our dedication to pushing the boundaries of organ preservation."

The introduction of the PancreasPak™ underscores Paragonix's leadership in organ preservation technology, expanding its impact from heart, lung, and liver to now include pancreas transplantation.






Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital Congress